主页 > 医药生命 >
【medical-news】血液检测法即将推出：有望早期检
阿尔茨海默血液检测“希望”
A US company is hoping to be the first to market a blood test which can detect early signs of Parkinson's and Alzheimer's disease.
一家美国公司正期望成为首家使血液检测上市的公司，该检测法可以监测帕金森和阿尔茨海默早期体征。
Several teams are working on such a test but Power3 Medical Products says its could be launched in Europe this summer, Chemistry and Industry reports.
《化学和工业》报道一些小组正在从事这样的检测，但是力量3医学产品说它今年夏天在欧洲是首创。
The diseases can currently only be diagnosed once symptoms develop.
这些疾病目前仅仅能在症状发展时被诊断出。
UK experts said the test sounded promising for detecting and monitoring the diseases but more work was needed.
英国专家说该方法对于监测和检测这些疾病是非常有前途的，但还需要对其进行更多的探索。
The company plans to launch the test in Greece first, before promoting it in the US by the end of the year.
公司计划年末在美国促销前先在希腊开展此检测。
It hopes the test could be launched in the UK early next year, if authorities are satisfied with trial results.
公司希望明年初该检测法可以在英国开展，如果当局满意它的实验结果的话。
Monitoring aid
监测辅助
The test, called NuroPro, measures levels of 59 biomarkers - proteins in the blood.
此检测法叫NuroPro，可以检测血液中59个生物标记蛋白水平
The relative levels of the markers is used to distinguish between Alzheimer's, Parkinson's and another neurodegenerative disease called Lou Gehrig's disease.
标记的相对水平被用于区别阿尔茨海默、帕金森和另一些叫做Lou Gehrig病的神经退行性疾病。
So far, more than 180 patients have been tested, with the company claiming between 60% and 70% success in identifying those with Alzheimer's, Parkinson's or Lou Gehrig's.
到目前为之已经检测了超过180名患者，公司声称识别阿尔茨海默、帕金森和Lou Gehrig病的成功率在60%~70%。
Clinical trials are under way in the US and Greece.
临床实验正在美国和希腊进行
Steve Rash, chief executive officer of the company, said: "There is currently no diagnostic test for any neurodegenerative disease on the market - diagnoses are currently based solely on a clinical diagnosis of symptoms."
公司执行总裁Steve Rash说：“目前市场上还没有诊断神经退行性变疾病的方法——目前的诊断单单基于临床症状的诊断。”
Kieran Breen, director of research at the Parkinson's Disease Society, speaking at the start of Parkinson's Awareness Week, said it was currently difficult to diagnose the condition.
帕金森疾病学会的研究主任Kieran Breen在帕金森觉醒周开始时发言说目前很难诊断疾病的情况。
But he added: "Whilst the NuroPro test sounds promising, a larger study would need to be carried out before it can be confirmed as being helpful in making the diagnosis of Parkinson's.
但是他补充说：“NuroPro检测法似乎很有前途，但是它在被认可为有助于诊断帕金森前还需要进行一项更大型的研究。”
"A blood test could also be particularly useful in monitoring the progression of Parkinson's and assessing agents or drugs that modify the rate of disease development."
“血液检测在监测帕金森进展和评估疾病发展等级的试剂或药物方面是十分有用的。”
The society is using the awareness week to highlight the need for people with Parkinson's to receive better specialist nursing care.
学会正在利用觉醒周来强调帕金森患者接受更好的专家护理的必要性。
A survey of 13,000 people with the disease last year found 40% had not spoken to a specialist nurse in the previous year.
去年一项包含13000位患者的调查发现40%的患者在过去的几年中没有和专家沟通交流。
Too complex?
太复杂？
Susan Sorensen, head of research at the UK Alzheimer's Society, said: "An effective blood test would present those diagnosed and their families with an opportunity to prepare for the impact of this devastating illness and make crucial decisions about their future.
英国阿尔茨海默学会研究领导Susan Sorensen说：“一项有效的血液检测可以使那些已经确诊的患者和他们的家庭为这个破坏性的疾病做准备，也为他们的未来做出关键的规划。”
But she said: "Opinion remains split on the potential effectiveness of a blood test, with some suggesting Alzheimer's is too complex to identify in this way.
但是她说：“观点在血液检测的有效性方面存在分歧，一些人认为阿尔茨海默太复杂用这种方法是检测不了的。”
Dr Sorensen said the test would also need to be usable on a large scale.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-03 05:11
医学,生命科学网